Concepedia

Publication | Closed Access

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

DOI

435

Citations

25

References

2010

Year

Michaëla Diamant, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Kristin Taylor, Michael Trautmann
The Lancet

References

YearCitations

EuroQol - a new facility for the measurement of health-related quality of life

Health Policy

1990

15.5K

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

David M. Nathan, John B. Buse, Mayer B. Davidson,

Diabetes Care

2008

3.8K

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

Ralph A. DeFronzo

Diabetes

2009

2.9K

World Medical Association Declaration of Helsinki

Not Available Not Available

JAMA

2000

2.3K

The assessment of binge eating severity among obese persons

Jim Gormally, Sionag Black, Sandy Daston,

Addictive Behaviors

1982

2.1K

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Ralph A. DeFronzo, Robert E. Ratner, Jenny Han,

Diabetes Care

2005

1.5K

The Treat-to-Target Trial

Matthew C. Riddle, Julio Rosenstock, John Gerich

Diabetes Care

2003

1.5K

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

John B. Buse, Robert R. Henry, Jenny Han,

Diabetes Care

2004

1.3K

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

David M. Kendall, Matthew C. Riddle, Julio Rosenstock,

Diabetes Care

2005

1.2K

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Daniel J. Drucker, John B. Buse, Kristin Taylor,

The Lancet

2008

1.1K

Page 1